WO2017111387A1 - 유사 세라마이드 화합물 및 그 제조방법 - Google Patents
유사 세라마이드 화합물 및 그 제조방법 Download PDFInfo
- Publication number
- WO2017111387A1 WO2017111387A1 PCT/KR2016/014717 KR2016014717W WO2017111387A1 WO 2017111387 A1 WO2017111387 A1 WO 2017111387A1 KR 2016014717 W KR2016014717 W KR 2016014717W WO 2017111387 A1 WO2017111387 A1 WO 2017111387A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- group
- hydroxy
- tridecyl
- Prior art date
Links
- RNBQFLPNQVVSSF-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(NC(CO)(CO)COC(CCC(Oc1c(C)c(C)c2OC(C)(CCCC(C)CCCC(C)CCCC(C)C)CCc2c1C)=O)=O)=O Chemical compound CCCCCCCCCCCCCCCC(NC(CO)(CO)COC(CCC(Oc1c(C)c(C)c2OC(C)(CCCC(C)CCCC(C)CCCC(C)C)CCc2c1C)=O)=O)=O RNBQFLPNQVVSSF-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N NC(CO)(CO)CO Chemical compound NC(CO)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 0 NC1(CO)CO*OC1 Chemical compound NC1(CO)CO*OC1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
- C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to novel pseudoceramide compounds and methods for their preparation.
- the surface of human skin is protected by the stratum corneum, and keratinocyte lipids in the constituents of the stratum corneum form a layered structure, which contributes to maintaining the skin's basic functions.
- Keratinocyte intercellular lipids consist of ceramides, cholesterol, free fatty acids, and the like. Among them, ceramide plays a central role in maintaining the moisture and barrier function of the stratum corneum, and when the content of ceramide in the stratum corneum decreases, the protective barrier function of the stratum corneum is reduced and various skin diseases are worsened.
- ceramides are used to extract from a variety of flora and fauna or microorganisms.
- ceramides present in these animals and plants and microorganisms are extremely small, and are difficult to extract and have a high production cost.
- the ceramide derived from nature is very low solubility in raw materials such as solvents commonly used in cosmetics, there is a problem that it is difficult to include in the product in a sufficient amount to exhibit the efficacy.
- the present inventors have completed the present invention as a result of trying to synthesize a similar ceramide compound having a structure similar to that of natural ceramide but having improved physical properties such as solubility.
- the present invention provides a novel pseudo ceramide compound represented by the following formula (1).
- R 1 is a C9 to C23 saturated or unsaturated aliphatic hydrocarbon group unsubstituted or substituted with a hydroxy group
- R 2 , R 3 , and R 4 are the same as or different from each other, and are each independently hydrogen or an alkyl group of C1 to C4,
- X is , or to be.
- the saturated aliphatic hydrocarbon group of C9 to C23 referred to herein may be linear or branched as the carbon-carbon bond is composed of only a single bond, for example, nonanyl group (C9: 0, nonanyl), decanyl group (C10 : 0, decanyl), undecanyl group (C11: 0, undecanyl), dodecanyl group (C12: 0, dodecanyl), tridecanyl group (C13: 0, tridecanyl), tetradecanyl group (C14: 0, tetradecanyl), Pentadecaneyl group (C15: 0, pentadecanyl), Hexadecaneyl group (C16: 0, hexadecanyl), Heptadecanyl group (C17: 0, heptadecanyl), Octadecanyl group (C18: 0, octadecanyl), Nonadecanyl group (C19: 0, nonadecanyl), icosany
- the C9 to C23 unsaturated aliphatic hydrocarbon group mentioned in the present specification includes one or more carbon-carbon double bonds or triple bonds and may be linear or branched, for example, nonenyl (C9: 1, nonenyl), Deceenyl (C10: 1, decenyl), undecenyl (C11: 1, undecenyl), dodecenyl (C12: 1, dodecenyl), tridecenyl (C13: 1, tridecenyl), tetradecenyl (C14: 1 , tetradecenyl), pentadecenyl group (C15: 1, pentadecenyl), hexadecenyl group (C16: 1, hexadecenyl), heptadesenyl group (C17: 1, heptadecenyl), octadecenyl group (C18: 1, octadecenyl), nona
- R 1 may be a tridecaneyl group, a tetradecaneyl group, a pentadecaneyl group, a hexadecaneyl group, or a heptadecanyl group, and more specifically, may be a tridecanyl group, a pentadecaneyl group, or a heptadecanyl group.
- alkyl group of C1 to C4 referred to herein may be a methyl group, ethyl group, propyl group, isopropyl group, or butyl group, but is not limited thereto.
- R 2 , R 3 , and R 4 may be the same as or different from each other, and each independently hydrogen or a methyl group, and more specifically, a methyl group.
- the compound of Formula 1 according to the present invention forms an asymmetric molecular structure including a tocopherol moiety, and thus, improved physical properties, such as high solubility, may be expected as compared to conventional pseudoceramide compounds having a symmetrical structure.
- improved physical properties such as high solubility
- it may provide an antioxidant effect to prevent aging of the biofilm.
- the compounds of formula 1 of the present invention include all isomers unless otherwise specified.
- the isomers include structural isomers and stereoisomers, wherein the stereoisomers include both optical isomers such as R / S isomers and diastereomers such as E / Z isomers.
- the present invention also provides a method for preparing a pseudo ceramide compound of Formula 1.
- Method for preparing a compound of formula 1 of the present invention can be represented by the following scheme 1, the step of reacting the compound of formula 2 and formula 3 to obtain a compound of formula 4;
- R 1 is a C9 to C23 saturated or unsaturated aliphatic hydrocarbon group unsubstituted or substituted with a hydroxy group
- R 2 , R 3 , and R 4 are the same as or different from each other, and are each independently hydrogen or an alkyl group of C1 to C4,
- Y is alkylidene, ethylidene, isopropylidene, cyclohexylidene, benzylidene or p-methoxybenzylidene,
- L 1 is a leaving group, and may be, for example, a hydroxy group, a halogen, an acyloxy group of C 1 to C 4, an alkyl carbonate group of C 1 to C 4, or an alkoxy group of C 1 to C 4.
- the halogen is F, Cl, Br or I
- the acyloxy group of C1 to C4 may be formate, acetate, propinoate, or butanoate
- the alkyl carbonate group of C1 to C4 is methyl carbonate, ethyl carbonate , Propylcarbonate or butyl carbonate
- the C1 to C4 alkoxy group may be methoxy, ethoxy, propoxy, isopropoxy or butoxy.
- a compound of Formula 4 may be prepared by reacting a compound of Formula 2 with a compound of Formula 3.
- R 1 to R 4 , X, Y and L 1 in Scheme 2 are as defined above.
- this step may be by nucleophilic acyl substitution or nucleophilic substitution.
- the nucleophilic acyl substitution reaction or nucleophilic substitution reaction is not particularly limited in the present invention can be carried out for 0.5 to 72 hours, preferably 1 to 12 hours in the range of 10 to 200 °C, preferably 10 to 100 °C. have.
- the solvent used is preferably an organic solvent, typically chloroform, dimethylformamide (DMF), methylene chloride (MC), diisopropyl ether, diethyl ether, tetrahydrofuran (THF), dimethylacetamide (DMA) , Dimethyl sulfoxide (DMSO), chlorobenzene, toluene, benzene, acetone and one selected from the group consisting of a mixed solvent thereof is possible, for example, chloroform, methylene chloride or acetone is used.
- organic solvent typically chloroform, dimethylformamide (DMF), methylene chloride (MC), diisopropyl ether, diethyl ether, tetrahydrofuran (THF), dimethylacetamide (DMA) , Dimethyl sulfoxide (DMSO), chlorobenzene, toluene, benzene, acetone and one selected from the group consisting of a mixed solvent thereof is possible, for example, chloro
- the reaction may further include a base, and for example, a base such as triethylamine, potassium carbonate, carbodiimide, or the like may be used.
- a base such as triethylamine, potassium carbonate, carbodiimide, or the like may be used.
- the compound of Formula 2 may be prepared by the method represented by Scheme 3. That is, the compound of Formula 2 is 1,3-diol in the starting material tris (hydroxymethyl) aminomethane, 2-Amino-2-hydroxymethyl-propane-1,3-diol, Formula 5)
- a compound of formula 6 may be prepared by introducing a protecting group, and the compound of formula 6 may be prepared by reacting the compound of formula 7 having a fatty acid group.
- tris (hydroxymethyl) aminomethane hydrochloride may be used as the starting material.
- R 1 and Y are as defined above, L 2 may be a leaving group, such as halogen, C1 to C4 acyloxy group, C1 to C4 alkyl carbonate group or C1 to C4 alkoxy group. .
- the compound of formula 5, the compound for introducing a protecting group to the 1,3-diol of the compound of formula 5, the compound of formula 6, and the compound of formula 7, which are the reactants of Scheme 2, may be prepared by various manufacturers including Aldrich. It can be purchased and used or manufactured by yourself.
- the 1,3-diol protecting group is not particularly limited in the present invention, various protecting groups known in the art may be used. For example, methylidene acetal, ethylidene acetal, isopropylidene ketal, cyclohexylidene ketal, benzylidene ketal, or p-methoxybenzylidene acetal protecting group can be used. In one embodiment of the present invention, an isopropylidene ketal protecting group was introduced using dimethoxypropane.
- the compound of formula 6 prepared by introducing a protecting group may be reacted with the compound of formula 7 to prepare a compound of formula 2 having a fatty acid group introduced through an amide bond.
- the compound of formula (7) is not particularly limited in the present invention, any one that satisfies the above definition, specifically palmitoyl chloride (CH 3 (CH 2 ) 14 COCl), myristoyl chloride (CH 3 (CH 2 ) 12 COCl), or stearoyl chloride (CH 3 (CH 2 ) 16 COCl).
- palmitoyl chloride CH 3 (CH 2 ) 14 COCl
- myristoyl chloride CH 3 (CH 2 ) 12 COCl
- stearoyl chloride CH 3 (CH 2 ) 16 COCl
- reaction conditions, temperature, pressure, time, etc. of each reaction is not particularly limited in the present invention, it may be appropriately adjusted by those skilled in the art.
- the compound of Chemical Formula 3 may be prepared by the step of reacting the compound of Chemical Formula 8 with the compound of Chemical Formula 9 or Chemical Formula 10.
- R 2 to R 4 and X are as described in Scheme 1, n is 1 or 2, A and B are the same as or different from each other, and each independently a hydroxyl group, a halogen, C1 to C4 It is an acyloxy group, C1-C4 alkyl carbonate group, or C1-C4 alkoxy group.
- the compound of Formula 8 includes ⁇ -, ⁇ -, ⁇ -, or ⁇ -tocopherol and derivatives derived therefrom, and may be purchased or used directly by various manufacturers including Aldrich.
- the compound of Formula 9 or Formula 10 is a linker , or As a compound for introducing into the formula (8), any of the above definitions are possible.
- the linker compound of Formula 9 may be succinic anhydride
- the linker compound of Formula 10 may be Succinic acid, chloroacetyl chloride, or ethyl bromoacetate.
- the present invention is not limited thereto.
- the compound of Chemical Formula 9 or Chemical Formula 10 may be purchased and used commercially, or may be prepared and used directly.
- reaction conditions are not particularly limited in the present invention, it may be appropriately adjusted by those skilled in the art.
- the compound of Formula 1 may be prepared by removing a protecting group from the compound of Formula 4.
- reaction conditions, temperature, pressure, time, etc. of the protecting group removing reaction are not particularly limited, and may be appropriately adjusted according to the protecting group used.
- the reaction may be by acidic aqueous solution treatment or the addition of hydrogen gas in the presence of a metal catalyst, and in accordance with a preferred embodiment of the present invention may be by acidic aqueous solution treatment.
- the acid used may be hydrochloric acid, nitric acid, sulfuric acid, or acetic acid.
- hydrochloric acid may be used.
- the condition of the protecting group removing reaction is not particularly limited in the present invention, and may be performed for 0.5 to 72 hours, preferably 1 to 12 hours in the range of -30 to 60 ° C, preferably -30 to 40 ° C.
- the solvent may be a polar solvent capable of dissolving an acid, and may be one selected from the group consisting of water, lower alcohols of C1-C4, tetrahydrofuran, and a mixed solvent thereof.
- tetrahydrofuran may be used.
- the compound of Formula 1 prepared through the above-described method is a substance having an excellent effect of recovering damaged skin and protecting the skin from external stimuli, and may be used as an effective material for the recovery and prevention of damaged skin.
- the compound of Formula 1 since the compound of Formula 1 has an asymmetric molecular structure including a tocopherol moiety, improved physical properties, such as improved solubility, can be expected, and when the tocopherol is released due to partial decomposition of pseudoceramide at the site of action, it provides an antioxidant effect. can do.
- the pseudoceramide compounds of the present invention are applicable to various fields. That is, it may be variously applied to cosmetics, pharmaceuticals, external preparations, food fields, etc. to which natural ceramides, synthetic ceramides, or similar ceramides are conventionally applied.
- the pseudoceramide compound of the present invention exhibits improved solubility as compared to the existing pseudoceramide compound and can be used as a substitute for natural ceramide, and can provide an antioxidant effect along with skin barrier function enhancement and maintenance effect.
- the pseudoceramide compound of the present invention can be widely used for external skin preparations and cosmetic compositions.
- 2-Amino-2-hydroxymethyl-propane-1,3-diol hydrochloride was used as a starting material (Helv. Chim. Acta 2003, 86, 2458-2470) (5-amino-2,2-dimethyl- [1,3] dioxan-5-yl) -methanol ((5-Amino-2,2-dimethyl- [1,3] dioxan-5-yl) -methanol (1.61 g) was dissolved in dichloromethane (50 mL), triethylamine (1.7 mL) was added, and palmitoyl chloride (2.75 g) was added to dichloromethane ( 10 mL) and slowly added dropwise.
- reaction solution was stirred at room temperature for 3 hours and washed with dilute hydrochloric acid solution and saturated sodium chloride solution.
- organic solution layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure, and then recrystallized with dichloromethane and hexane to obtain 2.5 g of a white solid of Formula 20.
- the compound of formula 20 (2.0 g) obtained in the above process (1) was dissolved in chloroform (20 mL), triethylamine (0.8 mL) was added, and the mixed anhydride filtrate obtained above was slowly added dropwise and stirred at room temperature for 2 hours.
- the reaction solution was diluted with dichloromethane (100 mL) and washed with dilute hydrochloric acid solution and saturated sodium chloride solution.
- the organic solution layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure, and then the product was separated using column chromatography to obtain 2.2 g of a transparent liquid of Chemical Formula 21.
- the compound of formula 21 (1.0 g) obtained in the above process (2) was dissolved in tetrahydrofuran (20 mL), 3N HCl (3 mL) was added, and the mixture was stirred at room temperature. It was confirmed that the starting material disappeared on TLC, diluted with dichloromethane (50mL) and washed with sodium bicarbonate solution and water. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure, and then separated by column chromatography to obtain 0.5 g of the compound of Formula 11 above.
- Example 2 Succinic Acid 3- Hydroxy -2- Hydroxymethyl -2- Tetradecanoylamino -Propyl ester 2,5,7,8 Tetramethyl -2- (4,8,12- Trimethyl - Tridecyl )- Croman Preparation of -6-yl ester compound
- the compound of formula 22 (3.72 g) obtained in the above process (1) was dissolved in dichloromethane (250 mL), and succinic acid mono- [2,5,7,8-tetramethyl-2- (4,8,12) -trimethyl-tridecyl) -chroman-6-yl] ester (5.3g) and N - (3- dimethylaminopropyl) - N-ethylcarbodiimide hydrochloride (N - (3-dimethylaminopropyl) - N -ethylcarbodiimide hydrochloride, 2.3 g) was added dropwise, followed by stirring at room temperature for 12 hours. The reaction solution was washed with water, and the organic solution layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure, and then separated by column chromatography to obtain 3.1 g of the compound of Chemical Formula 23.
- Example 3 Succinic Acid 3- Hydroxy -2- Hydroxymethyl -2- Octadecanoylamino -Propyl ester 2,5,7,8 Tetramethyl -2- (4,8,12- Trimethyl - Tridecyl )- Croman Preparation of -6-yl ester compound
- the compound of formula 26 (1 g) obtained in (1) above and the compound of formula 20 (0.8 g) obtained in Example 1 (1) were dissolved in acetone (50 mL), and potassium carbonate (1.32 g) powder was added. After the addition, the mixture was heated to reflux for 12 hours. After the reaction, the reaction solution was filtered and concentrated, diluted with dichloromethane, and washed with dilute hydrochloric acid and saturated aqueous sodium chloride solution. The organic solution was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure, and then separated by column chromatography to obtain 0.27 g of the compound of Formula 27.
- 0.1 g of the compound of Formula 15 was obtained by substantially the same method as (3) of Example 1, except that 0.34 g of the compound of Formula 28 obtained in (1) was used instead of the compound of Formula 21. .
- a compound of Chemical Formula 32 was used in the same manner as in (2) of Example 7, except that the compound of Chemical formula 22 (2.97 g) obtained in Example (1) was used instead of the compound of Chemical Formula 20. g was obtained.
- a compound of Chemical Formula 33 which was obtained in the same manner as in Example 7, (2), except that the compound of Chemical Formula 24 (3.42 g) obtained in Example (1) was used instead of the compound of Chemical Formula 20. g was obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (10)
- 제1항에 있어서,상기 R1은 C13 내지 C17의 포화 또는 불포화 지방족 탄화수소기이고, R2, R3, 및 R4는 수소 또는 메틸기인 것을 특징으로 하는 유사 세라마이드 화합물.
- 제1항에 있어서,상기 유사 세라마이드 화합물이숙시닉 애시드 2-헥사데카노일아미노-3-하이드록시-2-하이드록시메틸-프로필 에스터 2,5,7,8-테트라메틸-2-(4,8,12-트리메틸-트리데실)-크로만-6-일 에스터,숙시닉 애시드 3-하이드록시-2-하이드록시메틸-2-테트라데카노일아미노-프로필 에스터 2,5,7,8-테트라메틸-2-(4,8,12-트리메틸-트리데실)-크로만-6-일 에스터,숙시닉 애시드 3-하이드록시-2-하이드록시메틸-2-옥타데카노일아미노-프로필 에스터 2,5,7,8-테트라메틸-2-(4,8,12-트리메틸-트리데실)-크로만-6-일 에스터,(2-헥사데카노일아미노-3-하이드록시-2-하이드록시메틸-프로폭시)-아세틱 애시드 2,5,7,8-테트라메틸-2-(4,8,12-트리메틸-트리데실)-크로만-6-일 에스터,(3-하이드록시-2-하이드록시메틸-2-테트라데카노일아미노-프로폭시)-아세틱 애시드 2,5,7,8-테트라메틸-2-(4,8,12-트리메틸-트리데실)-크로만-6-일 에스터,(3-하이드록시-2-하이드록시메틸-2-옥타데카노일아미노-프로폭시)-아세틱 애시드 2,5,7,8-테트라메틸-2-(4,8,12-트리메틸-트리데실)-크로만-6-일 에스터,[2,5,7,8-테트라메틸-2-(4,8,12-트리메틸-트리데실)-크로만-6-일옥시]-아세틱 애시드 2-헥사데카노일아미노-3-하이드록시-2-하이드록시메틸-프로필 에스터,[2,5,7,8-테트라메틸-2-(4,8,12-트리메틸-트리데실)-크로만-6-일옥시]-아세틱 애시드 3-하이드록시-2-하이드록시메틸-2-테트라데카노일아미노-프로필 에스터, 또는[2,5,7,8-테트라메틸-2-(4,8,12-트리메틸-트리데실)-크로만-6-일옥시]-아세틱 애시드 3-하이드록시-2-하이드록시메틸-2-옥타데카노일아미노-프로필 에스터인, 유사 세라마이드 화합물.
- 화학식 2의 화합물 및 화학식 3을 반응시켜 화학식 4의 화합물을 수득하는 단계; 및상기 화학식 4의 화합물을 탈보호하여 화학식 1의 화합물을 수득하는 단계;를 포함하는 제1항의 유사 세라마이드 화합물의 제조방법:상기에서 R1은 하이드록시기로 치환 또는 비치환된 C9 내지 C23의 포화 또는 불포화 지방족 탄화수소기이고,R2, R3, 및 R4는 서로 같거나 다르며, 각각 독립적으로 수소 또는 C1 내지 C4의 알킬기이고,Y는 알킬리덴, 에틸리덴, 이소프로필리덴, 시클로헥실리덴, 벤질리덴 또는 p-메톡시벤질리덴이고,L1은 하이드록시기, 할로겐, C1 내지 C4의 아실옥시기, C1 내지 C4의 알킬 카보네이트기 또는 C1 내지 C4의 알콕시기이다.
- 제4항에 있어서,상기 R1은 C13 내지 C17의 포화 또는 불포화 지방족 탄화수소기이고, R2, R3, 및 R4는 수소 또는 메틸기인, 유사 세라마이드 화합물의 제조방법.
- 제6항에 있어서,상기 화학식 7의 화합물이 팔미토일 클로라이드(CH3(CH2)14COCl), 미리스토일 클로라이드(CH3(CH2)12COCl) 또는 스테아로일 클로라이드(CH3(CH2)16COCl)인, 유사 세라마이드 화합물의 제조방법.
- 제8항에 있어서,상기 화학식 9의 화합물이 무수숙신산인, 유사 세라마이드 화합물의 제조방법.
- 제8항에 있어서,상기 화학식 10의 화합물이 클로로아세틸 클로라이드 또는 에틸 브로모아세테이트인, 유사 세라마이드 화합물의 제조방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201680075704.2A CN108430985A (zh) | 2015-12-24 | 2016-12-15 | 一种类神经酰胺化合物及其制备方法 |
JP2018532245A JP6847955B2 (ja) | 2015-12-24 | 2016-12-15 | 類似セラミド化合物及びその製造方法 |
EP16879254.7A EP3395808B1 (en) | 2015-12-24 | 2016-12-15 | Pseudo-ceramide compound and preparation method therefor |
US16/064,764 US10183926B1 (en) | 2015-12-24 | 2016-12-15 | Pseudo-ceramide compound and preparation method therefor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0186636 | 2015-12-24 | ||
KR20150186636 | 2015-12-24 | ||
KR10-2016-0169877 | 2016-12-13 | ||
KR1020160169877A KR102644587B1 (ko) | 2015-12-24 | 2016-12-13 | 유사 세라마이드 화합물 및 그 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017111387A1 true WO2017111387A1 (ko) | 2017-06-29 |
Family
ID=59089582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/014717 WO2017111387A1 (ko) | 2015-12-24 | 2016-12-15 | 유사 세라마이드 화합물 및 그 제조방법 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017111387A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010093007A (ko) * | 2000-03-28 | 2001-10-27 | 김광수 | 세라마이드 및/또는 유사 세라마이드의 복합체가 표면처리된 메이컵용 화장료, 및 그의 제조방법 |
KR20010104451A (ko) * | 2000-04-28 | 2001-11-26 | 서경배 | 세라미드 유사 화합물 및 이의 제조방법, 및 이를함유하는 화장료 조성물 |
US20040005282A1 (en) * | 2002-01-22 | 2004-01-08 | L'oreal | Novel ceramides, compositions thereof and methods of use thereof |
US20090010968A1 (en) * | 2004-05-12 | 2009-01-08 | Jean-Claude Allart | Spot-on formulation useful for cosmetology and dermatology |
KR20130030093A (ko) * | 2011-09-16 | 2013-03-26 | (주)아모레퍼시픽 | 세라마이드를 포함하는 피부 외용제 조성물 |
KR20140070474A (ko) | 2012-11-30 | 2014-06-10 | (주)아모레퍼시픽 | 신규한 유사 세라마이드 화합물 및 그 제조방법 |
-
2016
- 2016-12-15 WO PCT/KR2016/014717 patent/WO2017111387A1/ko active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010093007A (ko) * | 2000-03-28 | 2001-10-27 | 김광수 | 세라마이드 및/또는 유사 세라마이드의 복합체가 표면처리된 메이컵용 화장료, 및 그의 제조방법 |
KR20010104451A (ko) * | 2000-04-28 | 2001-11-26 | 서경배 | 세라미드 유사 화합물 및 이의 제조방법, 및 이를함유하는 화장료 조성물 |
KR100352986B1 (ko) | 2000-04-28 | 2002-09-18 | 주식회사 태평양 | 세라미드 유사 화합물 및 이의 제조방법, 및 이를함유하는 화장료 조성물 |
US20040005282A1 (en) * | 2002-01-22 | 2004-01-08 | L'oreal | Novel ceramides, compositions thereof and methods of use thereof |
US20090010968A1 (en) * | 2004-05-12 | 2009-01-08 | Jean-Claude Allart | Spot-on formulation useful for cosmetology and dermatology |
KR20130030093A (ko) * | 2011-09-16 | 2013-03-26 | (주)아모레퍼시픽 | 세라마이드를 포함하는 피부 외용제 조성물 |
KR20140070474A (ko) | 2012-11-30 | 2014-06-10 | (주)아모레퍼시픽 | 신규한 유사 세라마이드 화합물 및 그 제조방법 |
Non-Patent Citations (1)
Title |
---|
HELV. CHIM. ACTA, vol. 86, 2003, pages 2458 - 2470 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020145514A1 (ko) | L-글루포시네이트 제조 방법 | |
WO2016064082A2 (ko) | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 | |
WO2011071314A2 (en) | Processes for preparing crystalline forms a and b of ilaprazole and process for converting the crystalline forms | |
WO2016129876A1 (ko) | 가소제 조성물, 수지 조성물 및 이들의 제조 방법 | |
WO2019240405A1 (ko) | 가소제 조성물 및 이를 포함하는 수지 조성물 | |
WO2013108959A1 (ko) | 글루탐산 유도체와 하이드록시 아닐린 또는 하이드록시기가 보호된 하이드록시 아닐린을 이용한 라말린 및 라말린 전구체의 합성방법 | |
WO2014065577A1 (ko) | 록소프로펜 (2s, 1'r, 2's) 트랜스-알코올의 제조방법 | |
WO2021118003A1 (ko) | 신규 혈관누출 차단제의 고수율 제조방법 | |
WO2017111387A1 (ko) | 유사 세라마이드 화합물 및 그 제조방법 | |
WO2020036382A1 (ko) | Sglt 저해제의 합성에 유용한 중간체의 제조 | |
WO2021194244A1 (ko) | 신규한 이노토디올의 제조방법 | |
WO2016108623A1 (en) | Novel method for preparing thienopyrimidine compound and intermediates used therein | |
WO2015119443A1 (ko) | 에스테르계 화합물, 이를 포함하는 가소제 조성물, 이의 제조방법, 및 이를 포함하는 수지 조성물 | |
WO2013002592A2 (ko) | 베툴론산의 고순도 정제방법, 고순도 베툴론산을 이용한 피페라진 베툴론산 아마이드 유도체의 제조방법과 그 유도체, 고순도 베툴론산을 이용한 고순도 비오씨-라이시네이티드 베툴론산 정제방법 | |
WO2022097903A1 (ko) | 비스-2-하이드록시에틸 테레프탈레이트의 고순도화 정제 방법 및 이를 포함하는 폴리에스테르 수지 | |
WO2022220610A1 (ko) | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 | |
WO2018062729A1 (ko) | 유사 세라마이드 화합물 및 그 제조방법 | |
WO2016159666A2 (ko) | 결정형 및 이의 제조방법 | |
WO2017018835A1 (en) | Method of preparing tdm-621 | |
WO2020017878A1 (en) | Novel catechol derivatives or salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same | |
WO2015115796A1 (ko) | 페길레이션된 7-디하이드로콜레스테롤 유도체 | |
WO2019088800A9 (ko) | 폴리에틸렌글리콜 유도체 및 이의 제조방법 | |
WO2023277590A1 (ko) | 알킬-d-알라니네이트의 제조방법, 알킬-d-알라니네이트, 알킬-d-알라니네이트 유도체, 및 이를 포함하는 의약품 또는 농업용품 | |
WO2018124847A1 (ko) | 에리불린 메실산염의 제조 중간체 및 그의 제조방법 | |
WO2022059948A1 (ko) | 소디움 타우로디옥시콜레이트의 대량 생산 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16879254 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018532245 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016879254 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016879254 Country of ref document: EP Effective date: 20180724 |